Skip to main content
Premium Trial:

Request an Annual Quote

CombiMatrix Stock Surges 79.7 Percent on Launch of Avian Flu Array

NEW YORK,Oct. 26 (GenomeWeb News) - Shares in CombiMatrix were up 79.7 percent, or $1.10, at $2.48 in mid-afternoon trading after the company launched an influenza DNA microarray.


According to CombiMatrix, the microarray can identify H5N1 bird flu and influenza A strains as well as provide information on mutations and unknown strains.


CombiMatrix's Influenza Microarray is included in its CatalogArray product line. It can detect and accurately type flu strains using a protocol that requires fewer than four hours, the company said. It is also designed to work on samples from humans, birds, pigs, horses, dogs, and other animals.


CombiMatrix is offering the system as a tool or as a service to researchers, and is also developing it as a field-deployable biodetector using electrochemical techniques.

The Scan

Study Finds Costs of Genome Sequencing May Limit Utility in Routine Care

Researchers report in the European Journal of Human Genetics that genome sequencing for rare disease diagnoses currently has similar benefits as less expensive exome analysis.

Study Suggests Nursing Mother's Diet Can Impact Offspring's Gut Microbiome

A new Cell Host and Microbe paper finds that mice whose mothers were fed a low-fiber diet during nursing experience lasting microbiota dysbiosis and increased obesity.

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.